Interleukin-1β has trophic effects in microglia and its release is mediated by P2X7R pore

Mastura Monif 1,5, Christopher A. Reid 2, Kim L. Powell 3, Katherine J. Drummond 4, Terrence J. O’Brien 3 and David A. Williams 1*

Abstract

Background: Enhanced expression of the purinergic P2X7 receptor (P2X7R) occurs in several neuroinflammatory conditions where increased microglial activation is a co-existing feature. P2X7 receptors can function either as a cation channel or, upon continued stimulation, a large pore. P2X7R-over-expression alone is sufficient to drive microglial activation and proliferation in a process that is P2X7R pore dependent, although the biological signaling pathway through which this occurs remains unclear. Once activated, microglia are known to release a number of bioactive substances that include the proinflammatory cytokine interleukin-1β (IL-1β). Previous studies have linked P2X7R stimulation to the processing and release of IL-1β, but whether the channel or pore state of P2X7R is predominant in driving IL-1β release is unknown and is a major aim of this study. In addition, we will determine whether IL-1β has trophic effects on surrounding microglia.

Methods: Electron microscopy and immunohistochemistry were used to delineate the sub-cellular localization of P2X7R and IL-1β in primary hippocampal rat cultures. FM1-43 fluorescent dye and confocal microscopy were used to quantify vesicular exocytosis from microglia expressing the pore-forming P2X7R versus a non-pore-forming point mutant, P2X7R G345Y. IL-1β in culture was quantified with an enzyme-linked immunosorbent assay (ELISA). IL-1β intracellular processing was blocked with inhibition of caspase 1 (with a synthetic peptide antagonist), and its extracellular form was neutralized with an IL-1β neutralizing antibody. Microglial activation and proliferation was quantified immunohistochemically with confocal microscopy.

Results: P2X7R and IL-1β were co-localized in lysosomes. Vesicular exocytosis was higher in microglia expressing the pore-forming P2X7R compared to those expressing the non-pore-forming mutant. There was increased IL-1β in cultures expressing the pore-forming P2X7R, and this proinflammatory cytokine was found to mediate the trophic effects of P2X7R pore in microglia. Inhibition of IL-1β production and function resulted in a significant decrease in P2X7R-mediated microglial activation and proliferation.

Conclusions: IL-1β is a mediator of microglial activation and proliferation, and its release/production is P2X7R pore dependent. Blockade of P2X7R pore could serve as a therapeutic target in alleviating the degree of inflammation seen in neurodegenerative and neoplastic conditions.

Keywords: Microglia, P2X7 receptor, Interleukin-1β, Activation, Proliferation, P2X7R pore, Neuroinflammation
Background

The pathogenesis of a number of diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, and human gliomas are thought to be a result of chronic neuroinflammatory processes. Microglial cells that exhibit specialized immune characteristics in the central nervous system play a crucial role in neuroinflammation. In a healthy CNS environment, microglia exhibit a quiescent morphology. However, under pathological conditions and in the setting on neuroinflammation, they undergo a process known as microgliosis. In this situation, microglia become activated with an enlarged soma, and acquisition of lamellapodia. They up-regulate the synthesis of a number of bioactive substances such as cytokines. The identity, amount, and temporal expression profile of these cytokines determines if the neuroinflammatory process is neuroprotective or ultimately lead to neurodegeneration [1].

Interleukin-1β (IL-1β) is a proinflammatory cytokine released by activated macrophages and microglia. There are numerous reports highlighting that the release of IL-1β from immunological cells is dependent on the activity of P2X7 receptor (P2X7R) [2, 4, 5, 16]. Here, we report that P2X7R over-expression in glioma-associate microglia and subsequent inhibition of P2X7R were sufficient to reduce glioma cell number [21]. There is an established link between P2X7R function and the release/production of the proinflammatory mediator IL-1β [2, 4, 5, 16]. Here, we reveal that IL-1β release is P2X7R pore dependent and that the blockade of the P2X7R pore could serve as a therapeutic option for alleviation of inflammation.

Methods

DNA constructs and site-directed mutagenesis.

Two enhanced green fluorescent protein (EGFP) fusion constructs used in this study for transfection of primary hippocampal astrocyte-microglia mixed cultures were as follows: P2X7R-EGFP where the wild type rat P2X7R (accession number: X95882) was fused to the N terminus of EGFP and P2X7R G345Y-EGFP where a point mutant of P2X7R was fused to the N terminus of EGFP as previously described [20]. This mutant, P2X7R G345Y-EGFP, was produced by targeting the glycine at position 345 in the rat P2X7R for substitution with tyrosine using a Quick-Change Site-Directed Mutagenesis Kit (Stratagene) with the following primers:

Forward: 5’ACC CTG TCC TAT TTC TAT TTG GCC ACC GTG TG
Reverse: 5’CA CAC GGT GCC CAA ATA GAA ATA GGA CAG GGT G

Base changes introducing the G345 to Y mutation are in bold type and underlined. All constructs were expressed under the influence of CMV promoter.

Primary hippocampal neuron-glia mixed cultures

Protocols for handling animals were reviewed and approved by the Animal Ethics Committee at The University of Melbourne, Australia. Primary hippocampal neuron-glia mixed cultures were prepared from P2-5 Sprague-Dawley rats as described previously [22]. Briefly, the animals were anesthetized by halothane inhalation, the brains were removed, and the hippocampi were dissected out and finely chopped. The hippocampal pieces were placed in an enzyme solution containing papain (200 units; Sigma-Aldrich) for 35 min at 37 °C. The hippocampal tissue was washed three times to remove all traces of papain, and the mixture was triturated to obtain a single cell suspension. The cells were plated into 12-well plates containing 18-mm poly-D-lysine (Sigma) coated coverslips (SDR Clinical Technology) at a density of 1.8 × 10^5 cells/well. The cultures were maintained in Minimum Essential Medium (Gibco, Invitrogen) with the following supplements: 1 mM glucose, penicillin-
streptomycin (5000 units/mL), 10 % heat inactivated fetal bovine serum (Gibco, Invitrogen), MITO+™ Serum Extender (Becton Dickinson), and 2 mM L-glutamine (Gibco, Invitrogen). The cells were cultured at 37 °C in a humidified incubator of 5 % CO₂/95 % O₂. Untransfected cultures contained ~48 % astrocytes and ~50 % microglia as assessed by immunohistochemistry using antibodies against glial fibrillary acidic protein (GFAP) and isolectin GS-1B4, respectively.

**Microglia-enriched cultures**

Initially, neuron-glia mixed cultures were prepared in 75 cm² flasks (JRH Biosciences). One animal was used per 75 cm² flask. After 14 days, the flasks of mixed neuron-glia cultures were shaken (Economy Orbital Mixer, U-lab) at 150 rpm for 4 h at 37 °C, to dislodge microglia loosely attached to underlying astrocytes. The medium containing microglia was then aspirated and centrifuged at 1000 rpm for 5 min. The pellet of microglia was re-suspended in supplemented culture medium and placed in 12-well plates containing poly-D-lysine-coated coverslips. One 75 cm² flask of mixed cultures was used for preparing four coverslips (wells) of a 12-well culture plate. There were 3.1 × 10⁴ microglia/coverslip at 24 h post-harvest. The media was changed once a week, and the cells were maintained in the incubator for further 1 week before use in the experiments. Purity was assessed by labeling with the microglial maker, isolectin GS-1B4, which identified 94 % of cells as microglia. Enzyme-linked immunosorbent assay (ELISA) experiments were conducted using microglia-enriched cultures to quantify the amount of IL-1β in culture.

**Transfection**

The exogenous plasmid DNA constructs, P2X7R-EGFP or P2X7RG345Y-EGFP, were individually introduced into cultured cells using a modified calcium phosphate transfection technique [23], with the aid of a CalPhos™ Mammalian Transfection Kit (Becton Dickinson Biosciences) according to the manufacturer’s protocols. The DNA concentration used was 2 µg/well of a 12-well culture plate (1.8 × 10⁵ cells/well). The expression of the exogenous constructs was monitored with an Olympus IX 81 fluorescence microscope 72 h post-transfection. This time was sufficient for the folding and trafficking, which are identical for each receptor type, and for the divergence of downstream effects of each exogenous P2X7R. The transfection efficiency was 20 %.

**Immunohistochemistry**

At 72 h post-transfection, neuron-glia mixed cultures were fixed for 15 min in a 4 % paraformaldehyde solution at room temperature. After fixation, the cells were washed once with phosphate-buffered saline (PBS), and non-specific protein binding sites were blocked with 2 % bovine serum albumin (Sigma) for 45 min at 37 °C. The following primary antibodies were used: mouse anti-GFP (final dilution, 1:200; Molecular Probes), anti-LAMP1 primary antibody (final dilution of 1:200; Abcam), isolectin GS-IB₄ from *Griffonia simplicifolia*, Alexa Fluor® 594 conjugate (final dilution of 1:100; Molecular Probes), anti-IL-1β (MAB501; final dilution, 1:100; Abcam), and OX-6 (anti-MHC II) (final dilution, 1:100; BD Pharmingen). Primary antibodies were made up in PBS, with 1 % Triton X-100 for permeabilization, and were incubated overnight at 4 °C. After three 5-min washes in PBS, the sections were incubated with the relevant secondary antibodies: Alexa Fluor® 488 (final dilution, 1:200; Molecular Probes) or Texas Red® X (final dilution, 1:200; Molecular Probes). All secondary antibodies were incubated overnight at 4 °C. After three 5-min washes in PBS, the samples were mounted with DAKO Fluorescent Mounting Medium. No staining was detected in the absence of the primary or secondary antibodies. Some preparations were counter-labeled with DAPI nuclear stain (5 µM; Molecular Probes).

**Confocal microscopy**

Seventy-two hours post-transfection, primary mixed cultures were viewed with an Olympus IX-81 fluorescence microscope equipped with a DG4 light source. Images were acquired with a 40× LucPlanFI Olympus (N.A. 0.6) air objective. For most experiments, the samples were simultaneously stained with two or three fluorescent probes, with dual or triple emission achieved through appropriately selected emission filters. Images were analyzed using MetaMorph (Universal Imaging Corporation®) software for assessment of microglial activation and proliferation. For live cell imaging, the cells were bathed in HEPES buffer (mM: NaCl 135, KCl 5, HEPES 10, Glucose 10, CaCl₂ 1, MgCl₂ pH 7.4) at room temperature (~25 °C).

**Electron microscopy**

The primary hippocampal neuron-glia mixed cultures were seeded onto thermox coverslips (ProSciTech). Seven days post culture, the cells were transfected with various DNA constructs. The transfected coverslips were fixed with 4 % paraformaldehyde and 0.1 % glutaraldehyde for 10 min at room temperature and transferred to the EM facility (The University of Melbourne) for embedding and grid sectioning (thin sections). Thin cryosections were prepared from glutaraldehyde and/or paraformaldehyde-fixed tissue after infusion with 2.3 M sucrose. The sections were then composed on carbon-coated nickel and picked up on a solid layer of 2 % gelatin in buffer. The grids were then prepared for immunohistochemistry.

On a sheet of wax (paraffin) for each grid, a ~0.5-mL drop of blocking buffer (1 % BSA made in PBS) was
placed. With fine forceps, the grids were individually positioned on top of the buffer (cells facing up) floating in the droplet. Non-specific binding sites were blocked for 10 min at room temperature. The grids were then transferred to drops of primary antibody (1:50 final dilution, anti-GFP antibody; Molecular Probes). The primary antibody was made up of PBS with 0.1 % Tween 20 (Amresco). The grids were incubated with primary antibody for 24 h at 4 °C, washed (three times) by gently transferring them to drops of washing buffer (sodium cacodylate trihydrate; Sigma), and then incubated for 2 h with drops of secondary antibody, anti-mouse IgG (whole molecule) gold conjugate, 10 nm (Sigma), diluted just before use to a concentration of 1:50. The grids were placed in a washing buffer (2 × 10 min washes), and the cells post fixed in 2 % glutaraldehyde in PBS and then washed with cacodylate buffer, for 3 × 2 min.

The grids were returned to the EM facility, stained with uranyl acetate in veronal buffer (pH 6.4) for 15 min, washed in water for 3 × 2 min, and dehydrated through 40 %, 75 %, 95 %, and 2 × 100 % ethanol for 2 min each. They were then left in 50/50 ethanol/LR (London resin) white for 10 min, then left in 100 % LR white for 2 × 10 min, and then sandwiched between Whatman filter papers with light pressure applied to remove residual liquid. After 1–2 h in an oven at 60 °C grids were counterstained with conventional uranyl acetate and lead citrate. The cells were viewed with an electron microscope with a minimum ×2000 magnification. Negative controls without primary antibody were generated for all experiments, and no signal was obtained.

Assessment of microglial activation
Microglial activation was assessed using morphological and immunohistochemical criteria as previously described [20]. Before analysis of activation, microglia were classified into two groups. Cells with an oval cell body containing a small volume of cytoplasm and long, thin, delicate, and radially branched processes were classified as ramified microglia [24]. Activated microglia were defined as having an enlarged soma (width greater or equal to 30 μm) [25, 26] and a broad-flattened appearance with the common presence of several lamellapodia [27]. This morphological classification was confirmed immunohistochemically by the use of microglial specific markers isoelectin GS-IB4 and CD-11b.

Assessment of microglial proliferation
We used isoelectin GS-IB4 as previously described [28], to quantify microglial proliferation. The transfected cells were identified with anti-GFP and a secondary Alexa Fluor® 488 antibodies. Microglia were selectively identified with isoelectin GS-IB4 staining, and all nuclei were stained with DAPI (Molecular Probes). Images were analyzed using MetaMorph (Universal Imaging Corporation”) software for assessment of proliferation.

Assessment of microglial exocytosis- FM1-43 experiments
Shedding of vesicular contents (exocytosis) from microglia expressing the pore- or non-pore-forming P2X7R was visualized by labeling the cells with the membrane permeant dye FM1-43 and measuring the changes in cell surface fluorescence upon P2X7R stimulation. ATP and BzATP were used to stimulate P2X7R. As well as labeling of vesicles and vesicular contents, the uptake of the styril (FM) dyes is generally utilized in the study of dynamics of vesicular release (endo- and exocytosis) [18]. FM1-43 is known to stain lysosomes and reveal lysosomal vesicular recycling [29]. Upon vesicular release, the cell surface FM1-43 fluorescence is expected to increase as the intracellular vesicle that is docking just inside the cell fuses with the cell membrane [30]. Thereafter, the membrane fluorescence is expected to transiently decrease as the contents are released.

The x,y coordinates of activated microglia expressing P2X7R-EGFP or P2X7R<sup>G345Y</sup>-EGFP were recorded for later imaging and all cells were loaded with 5 μM of FM1-43 for 5 min while the cells were bathed in PBS. Then, the cells were washed with BPS and incubated in HEPES buffer.

Fusion events were monitored as a time series of cell and the plasma membrane fluorescence. The temporal distribution of exocytosis events was obtained by defining regions of interest (ROI) of the cell surface and monitoring changes in membrane fluorescence using “TimeSeries” (LSM510 META software). All fluorescence values were corrected for background fluorescence levels.

Media exchange experiments
At 72 h post-transfection, the supernatant derived from cultures expressing P2X7R-EGFP or P2X7R<sup>G345Y</sup>-EGFP was transferred to untransfected 7-day-old primary hippocampal cultures, and the cultures were subsequently kept at 37 °C in a humidified incubator of 5 % CO<sub>2</sub>/95 % O<sub>2</sub> for a further 72 h. Thereafter, the cells were fixed in 4 % paraformaldehyde (10 min) and processed for immunohistochemistry with isoelectin GS-IB<sub>4</sub> to determine the number of microglia and DAPI nuclear stain to quantify the total number of cells.

IL-1β enzyme linked immunosorbent assay (ELISA)
IL-1β produced in the hippocampal microglia-enriched cultures expressing P2X7R-EGFP or P2X7R<sup>G345Y</sup>-EGFP was quantified with the aid of a Quantikine IL-1β ELISA kit (R&D Systems), according to the manufacturer’s protocols. Briefly, 72 h post-transfection, the cultures expressing P2X7R-EGFP or P2X7R<sup>G345Y</sup>-EGFP were exposed to BzATP (100 μM), a specific agonist of
P2X7R, for 30 min. At this time point, detectable amounts of ATP-induced IL-1β release have been previously reported [7]. Supernatants were collected and centrifuged at 2000 rpm for 3 min to pellet cellular debris. Triton X-100 (1 %) was added to the purified supernatants and gently mixed to dislodge IL-1β from the shed microvesicles [16] for assay by ELISA.

**Caspase 1 inhibition experiments**

Primary hippocampal cultures expressing P2X7R-EGFP or P2X7RG345Y-EGFP at 24 h post-transfection were exposed to N-Acetyl-TRP-GLU-His-Asp-AL (0.67 mg/mL; Sigma-Aldrich), a potent antagonist of ICE (caspase 1) [31, 32]. The inhibitor was left in culture from 24 to 72 h. The 24-h time point allows sufficient time for expression of the exogenous constructs (unpublished findings). At 72 h post-transfection (allowing sufficient time for downstream signaling cascades to develop), the cultures were fixed and processed for immunohistochemistry to measure the degree microglial activation and proliferation.

**IL-1β neutralization experiments**

The activity of the mature (extracellular) IL-1β was blocked with a specific IL-1β neutralizing antibody (R&D Systems). At 24 h post-transfection, the cultures expressing P2X7R-EGFP or P2X7RG345Y-EGFP were treated with a neutralizing antibody (1:50), and at 72 h post-transfection, the cultures were processed for immunohistochemistry and imaging to quantify microglial activation and proliferation.

**Results**

**P2X7R-activated microglia exhibited “nodular structures” containing intraluminal vesicles which expressed P2X7R**

P2X7R transfection is sufficient to drive microglial activation and proliferation [20]. Primary hippocampal cultures transfected with P2X7-EGFP showed that the cells expressing the exogenous construct co-localized with that of the microglial marker, isolectin GS-IB4 (Fig. 1a) and another maker of activated microglia OX-6 (MHC II) (Fig. 1b). The cells expressing P2X7-EGFP did not co-localize with that of an astrocytic marker, GFAP (Fig. 1b, c).

“Beaded” structures outside the cell that emanated from “nodular” outpouchings of the cell cytoplasm were evident in microglia (isolectin GS-IB4 positive) expressing exogenous P2X7R (Fig. 2a). Figures 2b, c shows high concentrations of P2X7R expression in the “nodular structures” of activated microglia (Fig. 2b, c).

Electron microscopy revealed that the “nodular structures” contained multiple round intraluminal vesicles ranging in size from 0.1 to 0.2 μm docked near the plasma membrane (Fig. 3a). Immuno-gold revealed that P2X7R receptor expressed on the membrane of vesicles as well as on nearby plasma membrane (Fig. 3b, c).

Immunohistochemical analysis indicates that sub-plasma membrane vesicles expressing P2X7R also expressed IL-1β (Fig. 3d). The expression of IL-1β co-localized with that of lysosomes, LAMP-1 (Fig. 3e, f).

**Microglia expressing the pore-forming P2X7R showed a higher degree of vesicular exocytosis**

Exocytosis was measured with FM1-43, a cell permeant fluorescent dye that loads lysosomal vesicles [29]. Figure 4a shows an activated microglia expressing wild-type P2X7R and stained with FM1-43. ATP caused an initial increase in plasma membrane fluorescence (indicating fusion of sub-plasmalemmal vesicles with the cell surface) and subsequent decrease in fluorescence (indicating extracellular release of vesicular contents) (Fig. 4b). The change in membrane fluorescence in response to ATP (3 mM) was significantly higher in cells expressing P2X7R-EGFP compared to those expressing P2X7RG345Y-EGFP (Fig. 4c), indicating that the cells expressing the pore-forming P2X7R were undergoing more exocytosis (release events/unit time). To confirm that the response was P2X7R specific, the experiment was repeated using BzATP (specific P2X7R agonist [33]) and oxATP (specific P2X7R antagonist, [34]). Figure 5a shows that when stimulated with BzATP, vesicles of ~200 μm diameter appeared on the surface of the cell followed by subsequent “release events” (see Additional file 1 for detailed images of the experiment in real time). The fused puncta often faded within 100–180 s. In response to BzATP, there was a significantly more vesicular exocytosis from microglia expressing the pore-forming wild-type P2X7R than those expressing the non-pore-forming mutant (G345Y) (Fig. 5b, c). This further confirmed that P2X7R pore is involved in exocytosis events in microglia and that the response is P2X7R specific, as it was blocked with oxATP.

**Media derived from primary hippocampal cultures expressing the pore-forming P2X7R contain a factor that is trophic to microglia**

Media from untransfected hippocampal cultures were replaced with the supernatants from cultures expressing either wild-type or mutant non-pore-forming P2X7R (P2X7RG345Y-EGFP). The absolute number and the proportion of microglia in culture were increased by supernatant derived from cultures expressing the wild-type construct compared to the mutant (Fig. 6a–c). This suggested that P2X7R pore-mediated biological “factor(s)” contained in the media were capable of driving microglial proliferation in untransfected cultures.

In response to BzATP (100 μM) stimulation, the extracellular medium from cultures expressing the wild-type P2X7R-EGFP contained a significantly higher amount of IL-1β, than that from cultures expressing non-pore-
forming P2X7R345Y-EGFP (Fig. 6d). If IL-1\textbeta is a potential facilitator of the P2X7R-mediated trophic effects on microglia, we would expect that inhibiting the action, or reducing the levels, of IL-1\textbeta would reduce the level of P2X7R-mediated microglial activation and proliferation of microglia.

**Microglial activation is inhibited following the blockade of IL-1\textbeta processing to its active form**

Processing of IL-1\textbeta to its active form was inhibited by blocking the intracellular actions of caspase 1 with a specific antagonist (N-Acetyl-TRP-GLU-His-Asp-AL). As a result, the total number of cells (Fig. 7c), the number of activated microglia expressing P2X7R (Fig. 7d), and the number of microglia (Fig. 7e) were all reduced. These results highlight the production of the active IL-1B to be an important step in P2X7R-mediated activation of microglia.

**Microglial activation and proliferation is reduced by neutralization of extracellular IL-1\textbeta**

When the potential effects of the extracellular, active form of IL-1\textbeta were abolished, microglial activation and proliferation were markedly reduced. Addition of an IL-1\textbeta neutralizing antibody to cultures expressing exogenous wild-type P2X7R caused significant reduction in the
total number of cells (Fig. 7f), the number of activated microglia expressing exogenous P2X7R (Fig. 7g), and the number of microglia (Fig. 7h).

Discussion
Here, we reveal that microglial vesicles adjacent to the plasma membrane co-express P2X7R and IL-1β and are likely to be of the lysosomal family of vesicles. Lysosomal vesicular exocytosis was more pronounced in activated microglia expressing wild-type P2X7R as opposed to those expressing a non-pore-forming mutant (P2X7G345Y). Cultures expressing wild-type P2X7R contained higher quantities of the extracellular (released) form of IL-1β than those expressing the non-pore-forming mutant. We also reveal that IL-1β is a key cytokine mediating the trophic effects of the P2X7R pore in microglia, as inhibition or neutralization of IL-1β resulted in significant reduction in P2X7R pore-driven microglia activation and proliferation. These findings highlight an important role for P2X7R pore formation and consequent production and release of IL-1β, indicating the critical role that is played by P2X7R pore formation in the hierarchy of neuroinflammation.

Activated microglia contain sub-plasma membrane vesicles that express IL-1β and P2X7R and these vesicles are of lysosomal origin
In this study, we showed that activated microglia displayed “nodular structures” as outpouchings of the cell cytoplasm containing discrete vesicles ranging 100–200 μm in diameter. These vesicles expressed P2X7R, IL-1β, and the lysosomal maker LAMP-1.
The proposed mechanisms of release of IL-1β include (i) exocytosis of secretory lysosomes, (ii) release of membrane spanning microvesicles derived from plasma membrane blebs, (iii) release of membrane-delimited exosomes derived from multivesicular bodies formed by invagination of endosomes, (iv) exocytosis of autophagosomes, and (v) direct release to the extracellular environment subsequent to cell death [15]. Our data support the lysosomal mode of release. Lysosomes were previously considered as end organelles in protein degradation, but recent studies have shown that lysosomes may also play roles in cellular signal transduction and secretion of signaling molecules [35, 36]. In cells of hemopoietic origin such as microglia, the lysosome can act as a secretory organelle [35, 36]. Previously it has been shown that FM143 and AM143 label lysosomal vesicles (by coinciding with lysosomal markers LAMP1 and cathepsin D), but not endosomes (no evidence of coin localization with endosomal marker EAA1) [30]. Our data, showing lysosomal localization of IL-1β and co-expression with P2X7R, indicates that it is likely that lysosomal exocytosis is involved in IL-1β release from microglia.

Expression of vesicles containing bioactive substances and their calcium-induced exocytosis were
long thought to be a property exclusive to neurons and neuroendocrine cells. However, significant evidence in the last 10 years indicates exocytosis of various factors from glia, in a process now called gliotransmission [37]. In astrocytes, FM1-43 only labels lysosomes, calcium-dependent exocytosis of lysosomes has been revealed by confocal microscopy [29, 38], and it was proposed that the lysosome is the major type of vesicle for calcium-regulated exocytosis. Thus, we reveal that microglia are similarly competent in undergoing exocytosis, and the process is P2X7R pore dependent.

The release of IL-1β is P2X7R pore dependent
In agreement with our findings, there are numerous prior reports that the release of IL-1β is dependent on P2X7R function [2, 5, 8, 10, 16, 39]. Grahames and colleagues reported that exogenous application of ATP resulted in the release of IL-1β from human monocytes, and the pharmacological profile was consistent with that of P2X7R stimulation [7]. Similarly, macrophages derived from P2X7R knockout mice did not release IL-1β in response to ATP stimulation [8]. Moreover, oxATP, an irreversible antagonist of both ion channel and pore conductances of P2X7R [34] was found to abolish ATP-induced IL-1β release from...
human macrophages [4]. Mariathasan and colleagues described a mechanism whereby P2X7R acted up-stream of the inflammasome to ultimately lead to the production and release of IL-1β [40].

In addition, P2X7R stimulation was also linked to the activation of NF-kB [41], a factor whose activity is thought to lead to enhanced transcription of IL-1β gene. As the experimental conditions used in all of these studies would involve stimulation, or conversely, antagonism of both ion channel and pore conductance, it is not possible to distinguish whether P2X7R channel or pore conductance was predominantly responsible for the production and release of IL-1β [40].

An attempt at this distinction between P2X7R channel and pore activities was made with P2X7R truncation mutants, where segments of the C terminus are removed to produce a mutant receptor without the capacity to form pores [53]. However, we have previously shown with P2X7R truncation mutants that while the C terminus is critical for P2X7R pore activity (the receptor needing 95 % of its C terminus to retain its pore function), the majority of P2X7R C-terminal truncation mutants suffer from altered folding, trafficking, and many rather than reaching their final plasmalemmal destination, aggregate in intracellular organelles [52]. In addition, the C-terminal domain of P2X7R is imperative in the interaction of the receptor with intracellular signaling cascades [54]. By deleting these regions, one would inevitably abolish the ability of the receptor to participate in potentially important cellular signaling

Fig. 5 a An activated microglia expressing P2X7R-EGFP, subsequently loaded with FM1-43. When this cell was then stimulated with BzATP (100 μM), vesicles of ~200-μm diameter appeared on the surface of the cell which was followed by subsequent “release events” (see Additional file 1 for detailed images of the experiment in real time). The exocytosis was relatively fast to begin with, starting within 15 s of application of the agonist, reaching its maximum within 90–120 s and continuing for a duration of 5 min. b Change in membrane fluorescence as a measure of vesicular exocytosis in FM-143-loaded cells in response to 100 μM BzATP. Change in membrane fluorescence from cells expression wild-type P2X7R (P2X7R-EGF; red line) and loaded with FM-143 as compared to those expressing the non-pore-forming mutant (P2X7RG345Y-EGFP; blue lines) as compared to those expressing wild-type P2X7R (P2X7R-EGF) but pre-treated with oxATP (purple lines) (100 μM). c The sum of exocytosis was presented as change in membrane fluorescence. In response to 100 μM BzATP, there was a significantly higher amount of vesicular exocytosis from microglia expressing the pore-forming wild-type P2X7R (P2X7R-EGF) as compared to those expressing the non-pore-forming mutant (P2X7RG345Y-EGFP) or those expressing the wild-type P2X7R with prior inhibition with P2X7R antagonist, oxATP (100 μM).
In the current study, we used instead P2X7R\(_{G345Y}\), a full-length, point mutant of P2X7R, with normal trafficking and expression properties with intact channel function but ablated pore-forming capacity [20] to show that the release of IL-1\(\beta\) was P2X7R pore dependent.

Our data indicates that the release of the cytokine is likely via lysosomal exocytosis, rather than cell lysis as suggested for macrophages [55], as P2X7R pore activity enhances microglial proliferation with no evidence of cytolysis [20]. In agreement, others have unequivocally dissociated the P2X7R-induced release of IL-1\(\beta\) from cytolysis [56] in human monocytes [57], human macrophages [4], and mouse peritoneal macrophages [3].

Li and colleagues found that pore dilation results from time-dependent alterations in the concentration of intracellular ions [58]. The P2X7R pore is unlikely to function as a transporter or conduit for the cytokine, due to the difference in size of the pore (≤900 Da) and the immature (34 kDa) and mature (17 kDa) forms of IL-1\(\beta\).
P2X7R pore formation may instead lead to activation of intracellular signaling cascades such as MAPK or Rho-effector kinase, or induction of NF-κB, ultimately leading to transcription, as well as caspase 1-induced processing and release of IL-1β via lysosomal exocytosis.

The trophic effects of P2X7R pore are mediated by IL-1β

Our findings are consistent with previous reports that basal proliferation of microglia is stimulated by IL-1β or tumor necrosis factor-α (TNF-α) [60]. The literature linking microglial activation and excess IL-1β release, with the pathogenesis of a number of neuroinflammatory conditions is extensive [61, 62]. Of particular note are observations that human IL-1 is elevated in cerebrospinal fluid derived from patients with brain injury [63], and the increased levels reported within brain lesions from patients with Alzheimer’s disease, multiple sclerosis, and HIV-associated dementia [64–67], and in CSF in Parkinson’s disease and Creutzfeldt-Jakob disease [68, 69].

Once released, IL-1β in turn can exert autocrine actions on microglia, and paracrine actions on astrocytes [70]. IL-1β can cause the production of a number of other proinflammatory bioactive substances (nitric oxide and IL-6) from astrocytes and microglia in culture [71, 72]. In turn, these substances have been implicated in the propagation of a number of CNS injuries and diseases [73].
Conclusions
In summary, the studies in this research showed that the release of IL-1β, while dependent on P2X7R function, requires P2X7R pore activity and is independent of cytolysis. Our results support a model where up-regulation of P2X7R and stimulation of pore activity leads to microglial activation and subsequent release of IL-1β through lysosomal exocytosis. This cytokine can potentially maintain or accelerate the trophic responses in microglia, with consequent deleterious cycles of neuroinflammation and neurodegeneration. There is evidence that polymorphisms in P2X7R that are associated with a loss or reduction of P2X7R function are associated with a decreased sensitivity to inflammation [9, 74]. Given the highly documented role of IL-1β in many neuropathological scenarios, our results suggest that specific manipulation of P2X7R pore could be utilized to reduce the degree of microglial activation, and this therapeutic strategy holds promise in the setting of Alzheimer’s and other neurodegenerative diseases, as well as neoplastic conditions where effective interventions are currently lacking.

Additional file

Additional file 1: Prior to the commencement of the video, activated microglia expressing P2X7R-EGFP were loaded with FM1-43. When the cells were then stimulated with BzATP (100μM) (at the commencement of the video), vesicles of ~200μm diameter appeared on the surface of the cell with subsequent ‘release events’ (seen in the video as fusion of green ‘beaded’ structures to the surface membrane). Exocytosis was relatively fast with application of the agonist, reaching its maximum by mid-section of the video. The entire duration (real-time) lasted during the video is 24.75 minutes. In total 100 images (1 image every 15 seconds) were captured for this experiment, and played at approximately 10 images per second. (MOV 6.25 mb)

Abbreviations
BzATP, 2′,3′-O-(4-benzoylbenzoyl)-ATP (agonist of P2X7R); FM1-43, fixable fluorescent probe used to study vesicular recycling; IL-1β, interleukin-1beta (cytokine); P2X7R, P2X7 receptor; P2X7RGly345Y, P2X7R with glycine to thryosine point mutation at position 345

Acknowledgements
This work was supported by the Australian Research Council (ARC).

Funding
Our study was funded by the Australian Research Council (ARC; application number DP0770955 DA Williams). In addition, a small grant was received from Royal Melbourne Hospital Watt-Geyer Oncology - Brain Cancer Research Award through Department of Neurology, Royal Melbourne Hospital (2015; Monif et al.). The funding bodies played no role in design of the study, collection, analysis, or interpretation of the data or in writing the manuscript.

Availability of data and materials
As part of our manuscript, no software or database was generated. However, we are happy to share any raw data, any detailed protocols, or any available information about various antibodies or other fluorescent probes.

Authors’ contributions
MM contributed in the conception and design of experiments as well as carrying out the experiments, data analysis, and drafting of the manuscript. The other authors assisted in the study design and interpretation of the data. DW also assisted in the study design and data interpretation as well as revising the manuscript and figures for final publication. All authors read and approved the final manuscript.

Authors’ information
- Dr. Mastura Monif MBBS, Bachelor of Biomed Sci Melb, Bachelor of Sci Honours and PhD Melb, is a Registrar at Royal Melbourne Hospital in Neurology Advanced Training. She is also a Honorary Fellow at The Department of Physiology (The University of Melbourne) where the majority of this research was conducted.
- Professor Terence J. O’Brien MBBS Melb, MD Melb, FRACP, is The James Stewart Chair of Medicine and Head of the Department of Medicine, The Royal Melbourne Hospital and Western Hospital, at The University of Melbourne. He is also a Consultant Neurologist at The Royal Melbourne Hospital.
- Professor David A. Williams BSc (Hons), PhD, heads the Confocal and Fluorescence Imaging Group in Physiology at The University of Melbourne. He is also the Program Director of Bachelor of Biomedicine and Associate Dean (Academic) in the Faculty of Medicine, Dentistry and Health Sciences.
- Dr. Katharine J. (Kate) Drummond MBBS, PhD, works as a neurosurgeon at Royal Melbourne Hospital, simultaneously conducting basic research into the mechanisms of glioma invasion. She heads the Central Nervous System Tumours at Royal Melbourne Hospital and is a national leader in surgical neuro-oncology and executive director of Neuro-oncology at the Victorian Comprehensive Cancer Centre.
- Dr. Christopher A. Reid, Bachelor of Pharmacy, PhD, is a Senior Research Fellow at Howard Florey Research Institute, in the laboratory of Ion Channels and Disease.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable to this study.

Ethics approval and consent to participate
Our study does not include any human participants. Our study involved the use of animals. Protocols for handling animals were reviewed and approved by the Animal Ethics Committee at The University of Melbourne, Australia (ethics application number: 1011651).

Author details
1Department of Physiology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria 3010, Australia.
2Howard Florey Institute, The University of Melbourne, Melbourne, Victoria 3010, Australia.
3Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria 3010, Australia.
4Department of Surgery, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria 3010, Australia.
5Department of Neurology, The University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria 3052, Australia.

Received: 24 November 2015 Accepted: 10 June 2016
Published online: 30 June 2016

References
1. Graeber MB, Streit WJ. Microglia: immune network in the CNS. Brain Pathol. 1990;1:2–5.
2. Sanz JM, Chiozzi P, Ferrari D, Colaianna M, Idzko M, Falzoni S, Felin R, Trabace L, Di Virgilio F. Activation of microglia by amyloid (beta) requires P2X7 receptor expression. J Immunol. 2009;182:4738–85.
3. Peregoaux D, Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem. 1994;269:15195–203.
4. Ferrari D, Chiozzi P, Falzoni S, Hanau S, Di Virgilio F. Puriﬁnization modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med. 1997;185:579–82.
26. Rogove AD, Lu W, Tsirka SE. Microglial activation and recruitment, but not extracellular ATP, mediates microglial pannexin-1 channel expression in the postnatal rat hippocampus. Hippocampus. 1998;8:458–467.

25. Dalmau I, Finsen B, Zimmer J, Gonzalez B, Castellano B. Development of a novel ATP receptor on microglia in the postnatal rat hippocampus. J Neurochem. 2001;76:125–132.

24. Sylver R, Shemon AN, Wiley J. Glu 496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes. J Immunol. 2004;172:3399–405.

23. Jiang M, Deng L, Chen G. High Ca(2+)-phosphate transfection efficiency for microvessicle formation and uptake and permeability changes in cells expressing the rat P2X7 receptor. J Biol Chem. 1997;272:11335–42.

22. Reid CA, Clements JD, Bekkers JM. Nonuniform distribution of Ca2+ channel subtypes on presynaptic terminals of excitatory synapses in hippocampal cultures. J Neurosci. 1997;17:7278–85.

21. Jiang M, Deng L, Chen G. High Ca(2+) phosphatase transfection efficiency enables single neuron gene analysis. Gene Ther. 2004;11:1303–11.

20. Soltys Z, Ziaja M, Pawlinski R, Setkowicz Z, Janeczko K. Morphology of reactive microglia in the injured cerebral cortex. Fractal analysis and complementary quantitative methods. J Neurosci Res. 2004;61:125–36.

19. Monif M, Hutten H. New methods for noninvasive and continuous recording of intracellular calcium in neurons. J Neurosci Res. 2001;63:90–100.
54. Kim M, Jang LH, Wilson HL, North RA, Surprenant A. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J. 2001;20:6347–58.
55. Hogquist KA, Unanue ER, Chaplin DD. Release of IL-1 from mononuclear phagocytes. J Immunol. 1991;147:2181–6.
56. Verhoef PA, Kertesy SB, Lundberg K, Kahlenberg JM, Dubyak GR. Inhibitory effects of chloride on the activation of caspase-1, IL-1beta secretion, and cytolysis by the P2X7 receptor. J Immunol. 2005;175:7623–34.
57. Rubartelli A, Bajetto A, Allavena G, Cozzolino F, Sita R. Post-translational regulation of interleukin 1 beta secretion. Cytokine. 1993;5:117–24.
58. Li M, Toombs GE, Silberberg SD, Swartz KJ. Physical basis of apparent pore dilation of ATP-activated P2X receptor channels. Nat Neurosci. 2015;18:1577–83.
59. Thorneberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356:768–74.
60. Flanary BE, Streit WJ. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia. 2004;45:75–88.
61. Rothwell NJ, Luheishi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000;23:618–25.
62. Shafer SS, Griffin WS, O’Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation. 2008;5:7.
63. Griffin WS, Sheng JG, Gentelman SM, Graham DI, Mrak RE, Roberts GW. Microglial interleukin-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neurosci Lett. 1994;176:133–6.
64. Griffin BS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, 3rd, Arac C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86:7611–5.
65. McGuinness MC, Powers JM, Bias WB, Schmeckpeper BJ, Segal AH, Gowda VC, Wesselingh SL, Berger J, Griffin DE, Smith KD. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinating lesions of X-linked adrenoleukodystrophy and multiple sclerosis. J Neuroimmunol. 1997;75:174–82.
66. Zhao ML, Kim MO, Morgello S, Lee SC. Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. J Neuroimmunol. 2001;115:182–91.
67. Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, Nelson SJ, Griffin WS. Gial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer’s disease. J Neurovirol Exp Neurol. 1994;5:231–8.
68. Van Everbroeck B, Dewulf E, Pals P, Lubke U, Martin JI, Cas P. The role of cytokines, astrocytes, microglia, and apoptosis in Creutzfeldt-Jakob disease. Neurobiol Aging. 2002;23:59–64.
69. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett. 1996;211:13–6.
70. Gibson RM, Rothwell NJ, Le Feuvre RA. CNS injury: the role of the cytokine IL-1. Vet J. 2004;168:230–7.
71. Basu A, Krady JK, Levison SW. Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res. 2004;78:151–6.
72. Wocjcechowsky C, Schoning B, Stoltenburg-Didinger G, Stockhammer F, Volk HD. Brain-IL-1 beta triggers astrogliaisis through induction of IL-6: inhibition by propranolol and IL-10. Med Sci Monit. 2004;10:B9325–30.
73. Mrak RE, Griffin WS. Gial and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005;26:349–54.
74. Denlinger LC, Angelini G, Schell K, Green DN, Guadarama AG, Prabhu U, Coursin DB, Bertsch PJ, Hogan K. Detection of human P2X7 nucleotide receptor polymorphisms by a novel monocyte pore assay predictive of alterations in lipopolysaccharide-induced cytokine production. J Immunol. 2005;174:4424–31.